Abstract
Tryptophan catabolism is a major metabolic pathway utilized by several professional and non-professional antigen presenting cells to maintain immunological tolerance. Here we report that 3-hydroxy-l-kynurenamine (3-HKA) is a biogenic amine produced via an alternative pathway of tryptophan metabolism. In vitro, 3-HKA has an anti-inflammatory profile by inhibiting the IFN-γ mediated STAT1/NF-κΒ pathway in both mouse and human dendritic cells (DCs) with a consequent decrease in the release of pro-inflammatory chemokines and cytokines, most notably TNF, IL-6, and IL12p70. 3-HKA has protective effects in an experimental mouse model of psoriasis by decreasing skin thickness, erythema, scaling and fissuring, reducing TNF, IL-1β, IFN-γ, and IL-17 production, and inhibiting generation of effector CD8+ T cells. Similarly, in a mouse model of nephrotoxic nephritis, besides reducing inflammatory cytokines, 3-HKA improves proteinuria and serum urea nitrogen, overall ameliorating immune-mediated glomerulonephritis and renal dysfunction. Overall, we propose that this biogenic amine is a crucial component of tryptophan-mediated immune tolerance.
Original language | English |
---|---|
Article number | 4447 |
Journal | Nature Communications |
Volume | 12 |
Issue number | 1 |
DOIs | |
State | Published - 21 Jul 2021 |
Bibliographical note
Publisher Copyright:© 2021, The Author(s).
Funding
The work was supported by the following grants: NIH-AG045223 and NIH-AI137198 to L.S.; the Swiss National Science Foundation, grant 310030_182528 to C.H.; Telethon GGP17094 and the Associazione Italiana per la Ricerca sul Cancro (AIRC; 19903) to F.F.; Sigrid Juselius Foundation to K.A.; NIH T32 DK007110 to S.C.; NIH-AI103338 and NIH-AI138552 to G.L.; NIH K12 GM102779/BETTR program to R.F.; Associazione Italiana per la Ricerca sul Cancro (AIRC 2019-23084) to U.G.; The Intramural Research Program of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (ZIG AR041181-11) to W.L.T. and M.G. European Union H2020 ERA project (No. 667824 – EXCELLtoINNOV) to M.V.
Funders | Funder number |
---|---|
National Institute on Aging | R01AG045223 |
National Institute of Arthritis and Musculoskeletal and Skin Diseases | ZIG AR041181-11 |
Division of Intramural Research, National Institute of Allergy and Infectious Diseases | AI137198 |
Horizon 2020 Framework Programme | 667824 – EXCELLtoINNOV |
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung | 310030_182528 |
Fondazione Telethon | GGP17094 |
Associazione Italiana per la Ricerca sul Cancro | 19903 |
Sigrid Juséliuksen Säätiö | NIH-AI138552, T32 DK007110, AIRC 2019-23084, K12 GM102779/BETTR, NIH-AI103338 |